Peptides DB

Research-centric peptide and protocol reference hub

GHK-Cu vs MOTS-C

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

GHK-Cu: Research use — not FDA-approvedMOTS-C: Research use — not FDA-approved

A data-driven comparison of GHK-Cu and MOTS-C (also searched as MOTS-C vs GHK-Cu) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

GHK-Cu centers on skin, while MOTS-C leans toward metabolic. On indexed research, GHK-Cu is ahead (GHK-Cu: 5 studies, Preclinical; MOTS-C: 3, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • GHK-Cu is strongest for skin; MOTS-C for metabolic.
  • Evidence: GHK-Cu Preclinical (5 studies) vs MOTS-C Human evidence (3).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
GHK-CuMOTS-C

At a glance

GHK-CuPreclinical

Copper Peptide | Skin Regeneration & Anti-Aging Compound

Strongest: SkinStudies: 5Level: Well Studied
MOTS-CHuman evidence

Mitochondrial-Derived Peptide | Metabolic Regulator

Strongest: MetabolicStudies: 3Level: Well Studied

GHK-Cu vs MOTS-C: side-by-side

MetricGHK-CuMOTS-C
ClassSkinLongevity
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalHuman evidence
Studies indexed53
Research levelWell StudiedWell Studied
Strongest effectSkin & aestheticsMetabolic & appetite
Healing & recovery4.02.0
Muscle & body comp1.01.0
Metabolic & appetite3.04.0
Neuro & mood2.01.0
Sleep & circadian1.00.0
Inflammation & immune4.03.0
Skin & aesthetics5.00.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyGHK-CuMOTS-C
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signalingMitochondrial-derived peptide; AMPK activation / metabolic regulation
RouteTopical / subcutaneousSubcutaneous injection (research use)

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is GHK-Cu?

Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.

Full GHK-Cu profile, mechanism & studies →

What is MOTS-C?

### Summary MOTS-C is a mitochondrial-derived peptide that has garnered attention for its potential roles in metabolic regulation and cellular stress responses. Emerging research suggests it may have implications in various health conditions, including cardiovascular diseases and placental function.

Full MOTS-C profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingGHK-Cu4.0/5 effect signal
MuscleEvenBoth ~1.0/5
MetabolicMOTS-C4.0/5 effect signal
NeuroGHK-Cu2.0/5 effect signal
SleepGHK-Cu1.0/5 effect signal
InflammationGHK-Cu4.0/5 effect signal
SkinGHK-Cu5.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack GHK-Cu and MOTS-C?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

GHK-Cu vs MOTS-C: side effects

GHK-Cu
  • improved skin texture18
  • localized irritation5
  • transient tingling4
  • gi upset1
  • headache1
MOTS-C

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

GHK-Cu has 5 approved studies indexed (Preclinical), and MOTS-C has 3 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is GHK-Cu or MOTS-C better?

It depends on your goal. GHK-Cu is strongest for skin; MOTS-C for metabolic. GHK-Cu has more indexed studies (5). See the goal-by-goal breakdown above.

Is GHK-Cu or MOTS-C better for weight loss?

MOTS-C shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is GHK-Cu or MOTS-C better for muscle?

Both land close on the muscle & body-composition axis.

Which has more research, GHK-Cu or MOTS-C?

GHK-Cu has 5 approved studies indexed (Preclinical); MOTS-C has 3 (Human evidence). Higher counts mean more to read, not proven superiority.

Can you stack GHK-Cu and MOTS-C?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of GHK-Cu vs MOTS-C?

GHK-Cu: community-reported improved skin texture, localized irritation, transient tingling. MOTS-C: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is GHK-Cu or MOTS-C FDA-approved?

GHK-Cu is a research-use compound and is not FDA-approved. MOTS-C is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is MOTS-C better than GHK-Cu?

For metabolic, MOTS-C has the edge; for skin, GHK-Cu does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

GHK-Cu and MOTS-C are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.